Comparative Efficacy and Safety of Obinutuzumab Versus Rituximab with Chemotherapy in Newly Diagnosed CD20-Positive Acute Lymphoblastic Leukemia

The primary objective of this study is to compare the **efficacy** of obinutuzumab and rituximab in adult patients with newly diagnosed CD20-positive acute lymphoblastic leukemia (ALL). Efficacy is defined as the proportion of patients achieving complete remission (CR) with minimal residual disease (MRD) level of less than 0.1% of bone marrow cells after one course of induction treatment. This is clinically relevant as achieving CR with low MRD is associated with improved long-term outcomes in ALL patients.

Secondary objectives include comparing the efficacy and safety of obinutuzumab and rituximab in these patients according to defined secondary endpoints. This comparison is crucial for understanding the overall benefit-risk profile of these treatments in the management of CD20-positive ALL.

The clinical trial involves adult participants diagnosed with **acute lymphoblastic leukemia** (ALL), specifically those with CD20-positive expression on at least 20% of blasts. The study population includes both male and female subjects aged 18 years and older. Participants are required to have newly diagnosed ALL and must provide signed written informed consent. The trial does not specify the total number of participants, as this information was not provided by the sponsor. The selection criteria include adequate contraception for women of child-bearing potential. The trial population is characterized by a vulnerable group, indicating a need for careful ethical considerations. Lifestyle factors such as diet, physical activity, or habits are not detailed in the available data.

The clinical trial is designed to evaluate the **efficacy** and safety of **obinutuzumab** versus **rituximab** in combination with chemotherapy for adult patients with newly diagnosed CD20-positive **acute lymphoblastic leukemia**. This is a randomized, double-blind, controlled trial with an estimated duration extending until December 31, 2025. The trial aims to compare the efficacy of the two drugs by measuring the proportion of patients achieving complete remission (CR) with minimal residual disease (MRD) levels of less than 0.1% of bone marrow cells after one course of induction treatment. Secondary endpoints include CR rates after consolidation, overall CR rates, and survival probabilities over a 24-month follow-up period.

Participants will be involved in the study for a maximum treatment period of 12 months. The trial will commence with a screening visit to confirm eligibility based on criteria such as age (≥18 years), newly diagnosed CD20-positive acute lymphoblastic leukemia, and signed informed consent. Following the screening, participants will undergo a series of study visits, including follow-up assessments to monitor treatment response and safety. The end-of-study visit will conclude the participant's involvement, assessing the final outcomes and any long-term effects.

Participants may be withdrawn from the study early if they experience significant adverse events, fail to adhere to the study protocol, or withdraw consent. The trial is structured to ensure rigorous monitoring and data collection, maintaining the integrity and reliability of the results. The study's design and procedures are aligned with ethical standards and regulatory requirements to ensure participant safety and the validity of the findings.

The clinical trial involves the administration of two experimental medications: **Rituximab** and **Obinutuzumab**, both of which are solutions for infusion. **Rituximab** is administered intravenously at a dosage of 375 mg/m², with a maximum total dose of 5625 mg/m² over a treatment period of up to 12 months. The active substance, **Rituximab**, is a protein of non-human origin, specifically designed for intravenous administration. The frequency of administration is determined by the study protocol, ensuring adherence to the maximum daily and total dose limits.

**Obinutuzumab** is also administered as an intravenous infusion, with a dosage of 1000 mg per administration and a maximum total dose of 15000 mg over a 12-month period. The active substance, **Obinutuzumab**, is similarly a protein of non-human origin, tailored for intravenous use. The dosing schedule is structured to comply with the specified maximum daily and total doses, as outlined in the clinical trial protocol.

In this study, **Rituximab** serves as the comparator treatment, while **Obinutuzumab** is the test treatment. Both medications are evaluated for their efficacy and safety in adult patients with newly diagnosed CD20-positive acute lymphoblastic leukemia. The primary objective is to compare the efficacy of these treatments, defined as the proportion of patients achieving complete remission with minimal residual disease (MRD) levels below 0.1% of bone marrow cells after one course of induction treatment. Participant compliance with the dosing schedule is monitored throughout the trial to ensure accurate assessment of treatment outcomes.

The efficacy of the clinical trial comparing **obinutuzumab** and **rituximab** in adult patients with newly diagnosed CD20-positive acute lymphoblastic leukemia (ALL) will be assessed through several parameters. The primary endpoint is defined as the proportion of patients achieving complete remission (CR) with minimal residual disease (MRD) level of less than 0.1% of bone marrow cells after one course of induction treatment. Secondary endpoints include the proportion of patients achieving CR with MRD level less than 0.01% after consolidation, CR rate after Induction I, overall CR rate in a 24-month follow-up, probability of overall survival (OS), relapse-free survival (RFS), event-free survival (EFS), cumulative incidence of relapse, and the rate of adverse events, all evaluated over a 24-month follow-up period.

The efficacy parameters will be measured and collected at specified timepoints throughout the trial, including after induction treatment and during the 24-month follow-up period. The analysis will involve comparing the efficacy outcomes between the two treatment groups, obinutuzumab and rituximab, in combination with chemotherapy. The trial is designed to provide a comprehensive evaluation of the efficacy of these treatments in achieving remission and improving survival outcomes in the specified patient population.